Travis J Yates1, Luis E Lopez1, Soum D Lokeshwar1, Nicolas Ortiz1, Georgios Kallifatidis1, Andre Jordan1, Kelly Hoye1, Norman Altman1, Vinata B Lokeshwar2. 1. Sheila and David Fuente Graduate Program in Cancer Biology, Sylvester Comprehensive Cancer Center (TJY, AJ, KH), Department of Urology (LEL, NO, GK, VBL), Honors Program in Medical Education (SDL), Department of Pathology (NA), Department of Cell Biology (VBL), Clinical Translational Science Institute (VBL), University of Miami-Miller School of Medicine, Miami, FL.Current affiliation: Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA (TJY). 2. Sheila and David Fuente Graduate Program in Cancer Biology, Sylvester Comprehensive Cancer Center (TJY, AJ, KH), Department of Urology (LEL, NO, GK, VBL), Honors Program in Medical Education (SDL), Department of Pathology (NA), Department of Cell Biology (VBL), Clinical Translational Science Institute (VBL), University of Miami-Miller School of Medicine, Miami, FL.Current affiliation: Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA (TJY). vlokeshw@med.miami.edu.
Abstract
BACKGROUND: Prevention and treatment of advanced prostate cancer (PCa) by a nontoxic agent can improve outcome, while maintaining quality of life. 4-methylumbelliferone (4-MU) is a dietary supplement that inhibits hyaluronic acid (HA) synthesis. We evaluated the chemopreventive and therapeutic efficacy and mechanism of action of 4-MU. METHODS: TRAMP mice (7-28 per group) were gavaged with 4-MU (450mg/kg/day) in a stage-specific treatment design (8-28, 12-28, 22-28 weeks). Efficacy of 4-MU (200-450mg/kg/day) was also evaluated in the PC3-ML/Luc(+) intracardiac injection and DU145 subcutaneous models. PCa cells and tissues were analyzed for HA and Phosphoinositide 3-kinase (PI-3K)/Akt signaling and apoptosis effectors. HA add-back and myristoylated Akt (mAkt) overexpression studies evaluated the mechanism of action of 4-MU. Data were analyzed with one-way analysis of variance and unpaired t test or Tukey's multiple comparison test. All statistical tests were two-sided. RESULTS: While vehicle-treated transgenic adenocarcinoma of the prostate (TRAMP) mice developed prostate tumors and metastases at 28 weeks, both were abrogated in treatment groups, without serum/organ toxicity or weight loss; no tumors developed at one year, even after stopping the treatment at 28 weeks. 4-MU did not alter the transgene or neuroendocrine marker expression but downregulated HA levels. However, 4-MU decreased microvessel density and proliferative index (P < .0001,). 4-MU completely prevented/inhibited skeletal metastasis in the PC3-ML/Luc(+) model and DU145-tumor growth (85-90% inhibition, P = .002). 4-MU also statistically significantly downregulated HA receptors, PI-3K/CD44 complex and activity, Akt signaling, and β-catenin levels/activation, but upregulated GSK-3 function, E-cadherin, and apoptosis effectors (P < .001); HA addition or mAkt overexpression rescued these effects. CONCLUSION: 4-MU is an effective nontoxic, oral chemopreventive, and therapeutic agent that targets PCa development, growth, and metastasis by abrogating HA signaling.
BACKGROUND: Prevention and treatment of advanced prostate cancer (PCa) by a nontoxic agent can improve outcome, while maintaining quality of life. 4-methylumbelliferone (4-MU) is a dietary supplement that inhibits hyaluronic acid (HA) synthesis. We evaluated the chemopreventive and therapeutic efficacy and mechanism of action of 4-MU. METHODS: TRAMP mice (7-28 per group) were gavaged with 4-MU (450mg/kg/day) in a stage-specific treatment design (8-28, 12-28, 22-28 weeks). Efficacy of 4-MU (200-450mg/kg/day) was also evaluated in the PC3-ML/Luc(+) intracardiac injection and DU145 subcutaneous models. PCa cells and tissues were analyzed for HA and Phosphoinositide 3-kinase (PI-3K)/Akt signaling and apoptosis effectors. HA add-back and myristoylated Akt (mAkt) overexpression studies evaluated the mechanism of action of 4-MU. Data were analyzed with one-way analysis of variance and unpaired t test or Tukey's multiple comparison test. All statistical tests were two-sided. RESULTS: While vehicle-treated transgenic adenocarcinoma of the prostate (TRAMP) mice developed prostate tumors and metastases at 28 weeks, both were abrogated in treatment groups, without serum/organ toxicity or weight loss; no tumors developed at one year, even after stopping the treatment at 28 weeks. 4-MU did not alter the transgene or neuroendocrine marker expression but downregulated HA levels. However, 4-MU decreased microvessel density and proliferative index (P < .0001,). 4-MU completely prevented/inhibited skeletal metastasis in the PC3-ML/Luc(+) model and DU145-tumor growth (85-90% inhibition, P = .002). 4-MU also statistically significantly downregulated HA receptors, PI-3K/CD44 complex and activity, Akt signaling, and β-catenin levels/activation, but upregulated GSK-3 function, E-cadherin, and apoptosis effectors (P < .001); HA addition or mAkt overexpression rescued these effects. CONCLUSION: 4-MU is an effective nontoxic, oral chemopreventive, and therapeutic agent that targets PCa development, growth, and metastasis by abrogating HA signaling.
Authors: Viktor Grünwald; Linda DeGraffenried; Douglas Russel; William E Friedrichs; Ratna B Ray; Manuel Hidalgo Journal: Cancer Res Date: 2002-11-01 Impact factor: 12.701
Authors: Frederik B Thomsen; Klaus Brasso; Laurence H Klotz; M Andreas Røder; Kasper D Berg; Peter Iversen Journal: J Surg Oncol Date: 2014-03-07 Impact factor: 3.454
Authors: Tiina A Jokela; Jukka Kuokkanen; Riikka Kärnä; Sanna Pasonen-Seppänen; Kirsi Rilla; Jyrki Kössi; Matti Laato; Raija H Tammi; Markku I Tammi Journal: Wound Repair Regen Date: 2013 Mar-Apr Impact factor: 3.617
Authors: Marie-Elena Brett; Heather E Bomberger; Geneva R Doak; Matthew A Price; James B McCarthy; David K Wood Journal: Integr Biol (Camb) Date: 2018-04-23 Impact factor: 2.192
Authors: M A Rice; R A Ishteiwy; F Magani; T Udayakumar; T Reiner; T J Yates; P Miller; C Perez-Stable; P Rai; R Verdun; D M Dykxhoorn; K L Burnstein Journal: Oncogene Date: 2016-02-22 Impact factor: 9.867
Authors: Vinata B Lokeshwar; Daley S Morera; Sarrah L Hasanali; Travis J Yates; Marie C Hupe; Judith Knapp; Soum D Lokeshwar; Jiaojiao Wang; Martin J P Hennig; Rohitha Baskar; Diogo O Escudero; Ronny R Racine; Neetika Dhir; Andre R Jordan; Kelly Hoye; Ijeoma Azih; Murugesan Manoharan; Zachary Klaassen; Sravan Kavuri; Luis E Lopez; Santu Ghosh; Bal L Lokeshwar Journal: Clin Cancer Res Date: 2020-02-24 Impact factor: 12.531
Authors: Sunny Guin; Yuanbin Ru; Neeraj Agarwal; Carolyn R Lew; Charles Owens; Giacomo P Comi; Dan Theodorescu Journal: Clin Cancer Res Date: 2015-10-21 Impact factor: 12.531
Authors: Rahul K Lall; Deeba N Syed; Mohammad Imran Khan; Vaqar M Adhami; Yuansheng Gong; John A Lucey; Hasan Mukhtar Journal: Carcinogenesis Date: 2016-06-22 Impact factor: 4.944